Commercialization of a Human Myocyte and Adipocyte Co-Culture System

人类心肌细胞和脂肪细胞共培养系统的商业化

基本信息

批准号：
7270329
负责人：
YOLANDA Renee LEA-CURRIE
金额：
$ 18.48万
依托单位：
ZEN-BIO, INC.
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-05-15 至 2008-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7270329
关键词：
Address Adipocytes Advisory Committees Age Area Basic Science Biological Assay Biopsy Cardiovascular Diseases Cell Culture System Cell Separation Cells Cellular biology Coculture Techniques Complex Condition Contract Services Contracts Cryopreservation Defect Depth Development Diabetes Mellitus Differentiation and Growth Disease Ensure Etiology Excision Goals Growth Factor Health Human In Vitro Incidence Individual Insulin Insulin Resistance Investigation Life Expectancy Link Maintenance Mechanics Metabolic Metabolic Diseases Methodology Methods Mission Molecular Monitor Muscle Muscle Cells Muscle Fibers Muscle satellite cell Myoblasts Non-Insulin-Dependent Diabetes Mellitus Obesity Patients Performance Peripheral Phase Phosphorylation Positioning Attribute Procedures Protocols documentation Qualifying Quality Control Rate Research Research Personnel Risk Factors Scientist Serum Services Signal Transduction Site Skeletal Muscle Skeletal system Small Business Funding Mechanisms Small Business Innovation Research Grant Strategic Planning Support of Research System Techniques Time Tissue Procurements Tissue Sample Tissues United States National Institutes of Health Validation abdominal fat adipocyte biology base blood glucose regulation cell type commercialization drug discovery glucose disposal human tissue insulin sensitivity insulin signaling novel strategies repository response satellite cell systems research

项目摘要

DESCRIPTION (provided by applicant): The well documented rise in obesity over the past two decades correlates with increased incidence rates of metabolic and cardiovascular disease. In response to the associated reduced life expectancy and expensive health problems the NIH has established an Obesity Research Task Force. The product development proposed in this SBIR application directly addresses the needs outlined in the Task Force's August 2004 Strategic Plan. One of the tenets of the plan is supporting research toward breaking the link between obesity and its related disorders. Increased abdominal adiposity correlates with defects in glucose homeostasis and is associated with decreased insulin sensitivity in peripheral tissue. Skeletal muscle is an important site of insulin-stimulated glucose disposal and is often the site of insulin resistance in obese individuals. To support research in this area, we propose to develop a well characterized, widely commercially available co-culture system of primary human skeletal myocytes and adipocytes. This cell system will allow researchers to investigate the complex interaction between two cell types directly involved in the etiology of Type 2 diabetes and metabolic disease. Zen-Bio has been providing cultured primary human cells commercially to researchers for the past 10 years and has established the expertise required for the completion of this proposal. The focus of the company has been adipocytes, however, scientists at Zen-Bio have expertise in the isolation, expansion, and differentiation of many types of human primary cells, including myoblasts. Phase I of this proposal consists of two aims. Aim I is expected to establish robust human satellite cell isolation, culturing, and myoblast differentiation protocols. Aim II will build on Aim I by optimizing and validating a co-culture system using human adipocytes and human skeletal muscle cells. Aim I will be achieved by systematically modifying existing protocols to suit the needs of a commercial myocyte system. Detailed activity analysis of each cell type in co-culture conditions will aid in optimizing the system in Aim II. Validation of the interaction between the two cell types in co-culture will be assessed by monitoring skeletal muscle cell insulin signal transduction. Phase II of the project consists of three aims. Aim I is to develop the necessary quality control assays for skeletal muscle cells prior to commercialization, Aim II is to develop a suite of skeletal muscle cell based contract assay services suitable for the study of metabolic disease, and Aim III is the establishment of a cell repository containing cultured adipocytes and skeletal muscle cells from the same patient. Multiple product offerings are expected from this proposal: a human skeletal muscle cell system, a co-culture system using adipocytes and skeletal muscle cells, contract assay services, and assay kits for skeletal muscle cells. At the completion of this project, a commercially available, fully validated human skeletal myocyte system, skeletal myocyte / adipocyte co-culture system, and related assay kits will be offered to researchers. The availability of these systems will provide opportunities for new approaches in the investigation of metabolic disease and a unique methodology to examine the complex interaction between these two cell types.

描述（由申请人提供）：有据可查的过去二十年肥胖人数的增加与代谢和心血管疾病发病率的增加相关。为了应对相关的预期寿命缩短和昂贵的健康问题，美国国立卫生研究院成立了肥胖研究工作组。本 SBIR 申请中提出的产品开发直接满足了工作组 2004 年 8 月战略计划中概述的需求。该计划的宗旨之一是支持旨在打破肥胖与其相关疾病之间联系的研究。腹部肥胖增加与葡萄糖稳态缺陷相关，并与外周组织胰岛素敏感性降低相关。骨骼肌是胰岛素刺激的葡萄糖处理的重要部位，并且通常是肥胖个体中胰岛素抵抗的部位。为了支持这一领域的研究，我们建议开发一种特征良好、广泛商业化的原代人类骨骼肌细胞和脂肪细胞共培养系统。该细胞系统将使研究人员能够研究直接参与 2 型糖尿病和代谢疾病病因学的两种细胞类型之间复杂的相互作用。 Zen-Bio 在过去 10 年里一直在商业上向研究人员提供培养的原代人类细胞，并已建立了完成该提案所需的专业知识。该公司的重点是脂肪细胞，然而，Zen-Bio 的科学家在多种类型的人类原代细胞（包括成肌细胞）的分离、扩增和分化方面拥有专业知识。该提案的第一阶段有两个目标。目标 I 预计建立强大的人类卫星细胞分离、培养和成肌细胞分化方案。 Aim II 将建立在 Aim I 的基础上，通过优化和验证使用人类脂肪细胞和人类骨骼肌细胞的共培养系统。目标 I 将通过系统地修改现有方案以满足商业肌细胞系统的需求来实现。对共培养条件下每种细胞类型的详细活性分析将有助于优化 Aim II 中的系统。将通过监测骨骼肌细胞胰岛素信号转导来评估共培养中两种细胞类型之间相互作用的验证。该项目第二阶段包括三个目标。目标 I 是在商业化之前开发骨骼肌细胞必要的质量控制检测，目标 II 是开发一套适合代谢疾病研究的基于骨骼肌细胞的合同检测服务，目标 III 是建立一个细胞含有来自同一患者的培养脂肪细胞和骨骼肌细胞的储存库。该提案预计将提供多种产品：人类骨骼肌细胞系统、使用脂肪细胞和骨骼肌细胞的共培养系统、合同检测服务以及骨骼肌细胞检测试剂盒。该项目完成后，将为研究人员提供市售的、经过充分验证的人类骨骼肌细胞系统、骨骼肌细胞/脂肪细胞共培养系统以及相关检测试剂盒。这些系统的可用性将为代谢疾病研究的新方法和检查这两种细胞类型之间复杂相互作用的独特方法提供机会。